Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 38

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 38
---
2024, the Nominating and Corporate Governance Committee met four times.

#### Science and Technology Committee
The Science and Technology Committee of the Board does not maintain a charter in order to preserve maximum flexibility for its activities. Some of the activities undertaken by the Science and Technology Committee include:

• reviewing the Company’s research and development strategy as well as the Company’s long-term strategic goals and objectives, and monitoring the Company’s progress in achieving such goals and objectives;

• advising the Board on scientific, technological, and research and development matters, and on strategic issues associated with the Company’s product pipeline and technology;

• reviewing and discussing the effectiveness and competitiveness of the Company’s position and strategies in relation to emerging scientific and technology trends and activities relevant to the success of the Company’s product pipeline and technology;

• reviewing the quality, direction, and competitiveness of the Company’s research and development programs, and product pipeline;

• reviewing the organization, resources and capabilities of the Company’s research, analytical, chemistry, manufacturing, and controls, and clinical departments;

• reviewing strategies and approaches to acquiring, in licensing, out licensing, and maintaining innovation and technology positions;

• advising the Board on the scientific, medical, and technical aspects of significant acquisitions, in licenses, out licenses, and other strategic business development transactions;

• assisting the Company in reviewing, as requested, the capabilities of the Company’s current and prospective key scientific, clinical, medical, or technical personnel and engagement with key opinion leaders, and the depth and breadth of the Company’s scientific resources;

• advising the Board, and the committees of the Board, as requested, with regard to performance and succession planning of the Company’s officers and other leadership of the research and development, manufacturing, medical, and other technical or scientific functions within the Company;

• reviewing and opining on the strategy for the Company’s intellectual property portfolio;

• providing counsel and know-how to the Company’s management in the area of research and development and the Company’s product pipeline and technology; and

• carrying out other tasks or providing other advice related to the Company’s product pipeline and technology as may be requested by the Board.

<div align='center'>22</div>

The Science and Technology Committee was formed in March 2024. The members of the Science and Technology Committee are Murat Kalayoglu, M.D., Ph.D., Kemal Malik, M.B.B.S., Michael Singer, M.D., Ph.D., and Timothy A. Springer, Ph.D. Dr. Kalayoglu serves as the Chairman of the Science